flutamide has been researched along with drospirenone in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| de Zegher, F; Ibáñez, L | 2 |
| Cabré, S; De Zegher, F; Ibáñez, L; Valls, C | 1 |
| Karaca, Z; Kelestimur, F; Unluhizarci, K | 1 |
| Canu, E; Fulghesu, AM; Melis, F; Melis, GB; Murru, G | 1 |
| Archer, DF; Jacot, T; Sabouni, R | 1 |
3 trial(s) available for flutamide and drospirenone
| Article | Year |
|---|---|
Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity.
Topics: Adiponectin; Adipose Tissue; Adolescent; Adult; Androgen Antagonists; Androstenes; Drug Therapy, Combination; Estrogens; Ethinyl Estradiol; Female; Flutamide; Hormone Antagonists; Humans; Hyperandrogenism; Hyperinsulinism; Hypoglycemic Agents; Intercellular Signaling Peptides and Proteins; Interleukin-6; Metformin; Mineralocorticoid Receptor Antagonists; Polycystic Ovary Syndrome; Proteins | 2004 |
Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of early, low-dose flutamide.
Topics: Adiponectin; Adolescent; Androstenes; Arteriosclerosis; Drug Therapy, Combination; Ethinyl Estradiol; Female; Flutamide; Humans; Hyperandrogenism; Intercellular Signaling Peptides and Proteins; Interleukin-6; Lipolysis; Metformin; Polycystic Ovary Syndrome; Proteins | 2004 |
Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of metformin at the start and after more than one year of therapy.
Topics: Adolescent; Adult; Androstenes; Arteriosclerosis; Drug Therapy, Combination; Ethinyl Estradiol; Female; Flutamide; Humans; Hyperandrogenism; Lipolysis; Metformin; Polycystic Ovary Syndrome; Time Factors | 2005 |
4 other study(ies) available for flutamide and drospirenone
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Hirsutism - from diagnosis to use of antiandrogens.
Topics: Androgen Antagonists; Androstenes; Cyproterone Acetate; Female; Finasteride; Flutamide; Hirsutism; Humans; Hyperandrogenism; Polycystic Ovary Syndrome; Spironolactone | 2013 |
Very low dose of flutamide in the treatment of hyperandrogenism.
Topics: Acne Vulgaris; Adolescent; Androgen Antagonists; Androstenes; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ethinyl Estradiol; Female; Flutamide; Hirsutism; Humans; Hyperandrogenism; Norpregnenes; Treatment Outcome; Young Adult | 2018 |
Drospirenone Effects on the Plasminogen Activator System in Immortalized Human Endometrial Endothelial Cells.
Topics: Aldosterone; Androgen Antagonists; Androstenes; Cell Line; Endometrium; Endothelial Cells; Female; Flutamide; Humans; Mineralocorticoid Receptor Antagonists; Plasminogen Activator Inhibitor 1; Receptors, Mineralocorticoid; Tissue Plasminogen Activator | 2021 |